$ALPMY News Article - Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV (enfortumab vedotin-ejfv) with KEYTRUDA (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Meta https://marketwirenews.com/news-releases/aste...17718.html